Adam Schoen, co-practice group leader of both Brown Rudnick LLP‘s global IP and life sciences practice group, has extensive experience in advising clients in the life sciences industry on patents, IP strategy, and transactions, as well as developing and implementing worldwide patent strategies. Schoen notably advised biotechnology startup company Kate Therapeutics on IP matters in its $1.1 billion sale to Novartis.
Legal 500 Editorial commentary
Phone
+1.617.856.8132
Email
Profile

Accolades

Boston Elite

Profile

Work Department
Intellectual Property and Life Sciences
Position

Partner

Career

Adam Schoen is a partner and co-practice group leader of Brown Rudnick's Global Intellectual Property Practice Group and Global Life Sciences Group. Adam has been in the life sciences industry for over 20 years and has over 15 years of experience advising life sciences and medical device funds, companies, and academic institutions. Adam helps his clients build, grow, invest in, buy, and sell companies of all sizes all over the world. Adam’s practice is multidisciplinary, encompassing all aspects of patent preparation and prosecution, portfolio development, product clearance, freedom to operate analysis, intellectual property due diligence, licensing, and other agreement work.

Adam has experience developing and implementing worldwide patent strategies across the life sciences industry. He works with a variety of technologies, such as small molecule therapeutics, biologics (including gene therapies and immunotherapeutics), gene editing technology, next generation sequencing technologies, microfluidics and droplet based technologies, diagnostics (including cancer and fertility diagnostics), medical device technology (ophthalmology, cardiology, orthopedics, otolaryngology, neurology, and spine), medical imaging technology (ultrasound and OCT), mass spectrometry, and digital health products.

Prior to law school, Adam was a scientist of analytical chemistry for ArQule, a combinatorial chemistry and drug discovery company, and a scientist at Millennium Pharmaceuticals.

Content supplied by Brown Rudnick LLP

Key clients

  • Kate Therapeutics Vor Bio Voxelron Latigo Biotherapeutics Climb Bio Navigator Medicines AllRock Bio

Work highlights

Advised biotech startup Kate Therapeutics on all IP-related aspects of its $1.1 billion sale to Novartis, which includes an upfront cash payment and milestone-based add-ons.
Represented Vor Bio in an exclusive license agreement with China-based RemeGen, granting Vor Bio global rights (excluding China, Hong Kong, Macau, and Taiwan) to develop and commercialize Telitacicept.
Advised Latigo Biotherapeutics on IP matters for its $150 million Series B financing, led by Blue Owl Capital with participation from Deep Track Capital, Access Biotechnology, Qatar Investment Authority, and Sanofi Ventures. The funds will advance Latigo’s Nav1.8 inhibitors for non-opioid pain treatment and support its broader AI-driven drug development pipeline.